Pfizer's Ghost at the Merck-Schering Banquet
Like Banquo's ghost at Macbeth's table, Pfizer Inc. haunts the new collaboration between Merck & Co. Inc. and Schering-Plough Corp. Indeed, without Pfizer, these companies may never have gotten together at all in this innovative co-development and co-promotion alliance which serves both as a patent-extension strategy and an alternative to mergers.
You may also be interested in...
Schering's willingness to take over the marketing responsibilities for Novartis's Foradil respiratory drug, which has been largely superseded by combination products, to some degree measures the depths of Schering's troubles. But it also indicates the kinds of competition small-company in-licensers are likely to face. A whole industry of in-licensing focused players has grown up to sell the non-core products of Big Pharma: if Schering is any indication, the competition for these products is likely to get even more intense.
Data presented at AAAI meeting show reduced annualized asthma exacerbation rates across all patient populations, but doctors are unlikely to switch patients served well by existing biologics.
The RNA drug’s accelerated approval brings Sarepta’s exon-skipping market share to nearly 30%.